-
KROS Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Keros Therapeutics (KROS)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 561.38 mm | 561.38 mm | 561.38 mm | 561.38 mm | 561.38 mm | 561.38 mm |
Cash burn (monthly) | (no burn) | (no burn) | 17.75 mm | 17.57 mm | 15.34 mm | 13.41 mm |
Cash used (since last report) | n/a | n/a | 36.92 mm | 36.54 mm | 31.89 mm | 27.88 mm |
Cash remaining | n/a | n/a | 524.46 mm | 524.84 mm | 529.49 mm | 533.50 mm |
Runway (months of cash) | n/a | n/a | 29.5 | 29.9 | 34.5 | 39.8 |
13F holders | Current |
---|---|
Total holders | 166 |
Opened positions | 39 |
Closed positions | 39 |
Increased positions | 74 |
Reduced positions | 29 |
13F shares | Current |
---|---|
Total value | 564.15 bn |
Total shares | 43.29 mm |
Total puts | 669.65 k |
Total calls | 646.45 k |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
FMR | 5.54 mm | $87.75 bn |
Pontifax Management 4 G.P. | 4.73 mm | $109.98 mm |
BlackRock | 2.73 mm | $43.20 bn |
Vanguard | 1.96 mm | $30.98 bn |
Braidwell | 1.89 mm | $29.99 bn |
Darwin Global Management | 1.69 mm | $26.71 bn |
Arkin Moshe | 1.37 mm | $79.29 mm |
STT State Street | 1.20 mm | $19.05 bn |
Holocene Advisors | 1.20 mm | $19.00 bn |
Alkeon Capital Management | 1.10 mm | $17.43 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Feb 25 | Yung H. Chyung | Common Stock | Grant | Acquire A | No | No | 0 | 44,000 | 0.00 | 44,000 |
18 Feb 25 | Regnante Keith | Common Stock | Grant | Acquire A | No | No | 0 | 44,000 | 0.00 | 44,000 |
18 Feb 25 | Christopher Rovaldi | Common Stock | Grant | Acquire A | No | No | 0 | 60,000 | 0.00 | 60,000 |
8 Nov 24 | Yung H. Chyung | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 67.91 | 110,000 | 7.47 mm | 110,000 |